摘要
目的评价康妇炎胶囊联合抗菌药物治疗盆腔炎性疾病疗效和安全性。方法检索中国知网、万方、维普、中国生物医学文献数据库,Pubmed,Embase,The Cochrane Library等数据库,纳入康妇炎胶囊联合抗菌药物对比单用抗菌药物治疗盆腔炎性疾病的随机对照试验,检索时间为建库至2018-08-01。采用Rev Man5.3软件进行Meta分析。结果共纳入20个RCT,2820例患者。两组临床治愈率、缓解下腹疼痛症状、改善盆腔体征、减少盆腔积液、降低复发率疗效比较,差异均有统计学意义(P<0.05)。两组减小盆腔包块疗效、不良反应发生率比较,差异无统计学意义(P>0.05)。结论抗菌药物基础上加用康妇炎胶囊治疗盆腔炎性疾病可提高临床疗效,减少盆腔炎性疾病后遗症的发生,且不增加不良反应。受纳入文献数量及质量限制,该结论需开展高质量RCT进行验证。
Objective To evaluate the efficacy and safety of Kangfuyan capsule combined with antibiotics in the treatment of pelvic inflammatory diseases.Methods The CNKI,WANFANG,VIP,CBM,Pubmed,Embase and The Cochrane Library were searched from their date of foundation to August 1,2018.The randomized controlled trial were included on the treatment for pelvic inflammatory diseases by Kangfuyan capsules with antibiotics or by antibiotics alone.Meta-analysis was conducted using RevMan5.3 software.Results Totally 20 reports(2820 subjects)were included.The clinal of cure rate,pain relief,pelvic signs relief,pelvic effusion reduction,decrease in recurrence rate had statistical difference between two groups(P<0.05).There was no significant difference in adverse reaction rate or the effect in reducing pelvic mass(P>0.05).Conclusion Kangfuyan capsule combined with antibiotics in treating pelvic inflammatory disease can improve clinical efficacy,reduce the occurrence of sequelae of pelvic inflammatory disease,without increasing adverse reactions.A large quantity of samples and long-term clinical studies need to be conducted to confirm the effects.
作者
黄利
魏绍斌
罗梅
张赛
李茂雅
HUANG Li;WEI Shao-bin;LUO Mei;ZHANG Sai;LI Mao-ya(Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China)
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2019年第4期455-461,共7页
Chinese Journal of Practical Gynecology and Obstetrics
基金
中国中医科学院基本科研业务专项资金:中医药单用/联合抗生素治疗感染性疾病的七项循证临床实践指南(ZZ10-018-02
Z0465)
